Xe 5000 hematology analyzer

Blood samples were drawn immediately after the patients’ admission to the emergency department. The serum biomarkers evaluated upon admission included white blood cell count in giga/L (XE 5000 Hematology Analyzer; flow cytometric, Sysmex, Germany), hemoglobin value in g/dl (XE 5000 Hematology Analyzer; photometric, Sysmex, Germany), hematocrit value in % (XE 5000 Hematology Analyzer; cumulative pulse height summation, Sysmex, Germany), cholinesterase in U/L (ADVIA Chemistry XPT^® CHE Assay, Siemens, Germany), blood glucose level in mg/dl (ADVIA Chemistry XPT^® GLUH_c Assay, Siemens, Germany), serum lactate level in mmol/L (ADVIA Chemistry XPT^® LAC Assay, Siemens, Germany), troponin I in µg/dl (ADVIA Centaur XPT^®, TNI-Ultra Assay, Siemens, Germany), cortisol value in µg/dl (ADVIA Centaur XPT^®, Cortisol Assay, Siemens, Germany), CRP in mg/L (ADVIA Chemistry XPT^® wrCRP Assay, Siemens, Germany), and albumin level in g/L (ADVIA Chemistry XPT^® ALB_c Assay, Siemens, Germany). Moreover, the CRP/albumin ratio was calculated by the division of the CRP value to the albumin value obtained at the time of patient admission.

All patients with moderate-to-severe active UC, who started oral tacrolimus treatment at our hospital between January 2009 and December 2017, were retrospectively enrolled. As the aim of this study was to evaluate the prognostic value of the NLR for long-term outcome, patients who were nonresponsive to tacrolimus by week 12 were excluded. Patients who were not receiving IMs for maintaining remission at the time of withdrawal of tacrolimus or those receiving anti-TNF agents were also excluded.
The diagnosis of UC was based on clinical, endoscopic, and histopathologic findings. Demographic, clinical, and laboratory data were obtained from the medical records. The differential white blood cell count was analyzed using an XE-5000 hematology analyzer (Sysmex, Kobe, Japan), according to the manufacturer’s protocol. In each case, the NLR was calculated from a blood sample by dividing the absolute neutrophil count with the absolute lymphocyte count.
Patients were followed up from the time of tacrolimus administration to clinical relapse, cessation of IM maintenance therapy, loss to follow-up, or until the end of October 2018.

The complete blood count (CBC) test was carried out with a Sysmex XE-5000 hematology analyzer (Sysmex, Kobe, Japan). Data regarding white blood cells (WBC), hemoglobin, hematocrit, and platelets were collected. The PLT-O (fluorescence) channel of Sysmex instrument was used for this study. Residual whole blood was diluted with saline (0.9% NaCl) to desired platelet count (10,000/μL) by the data of CBC before flow cytometric analysis. As the platelet count of MDS patients varies among individuals and appears to be lower than that of healthy controls, flow cytometric analysis was performed with diluted whole blood containing the same platelet count.

Patients’ platelet parameters were obtained from the data of routine preoperative examination after admission. Patients were drawn venous blood after admission which would transport to the laboratory within 1 hour and measured by Sysmex XE5000 hematology analyzer (Sysmex). All microscopic slides and immunohistochemistry of tissue excised intraoperatively were reviewed by two pathologists. Computed tomography (CT) scan and lymph node metastasis sites were used to detect metastatic status.

After sacrificing the mice, blood aliquots were collected in 300 µL tubes (VACUPLAST) containing ethylenediaminetetraacetic acid (EDTA‐K2) and carefully mixed by inversion in a homogenizer (Electra—Homolaby 22T) for hematological tests that were performed in an automated hematology analyzer (Sysmex XE-5000 hematology analyzer, Sysmex, Kobe, Japan) to establish the following parameters: RBC, red blood cells; HB, hemoglobin; HCT, hematocrit; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PLT, platelet count; VGM, mean corpuscular volume; WBC, white blood cells; LYM, lymphocytes; NEU, neutrophils; EOS, eosinophils; MON, monocytes; and BASO, basophiles. For biochemical analysis of serum, aliquots of blood were deposited in tubes (10 × 45 mm, maximum volume 500 µL—VACUPLAST) containing coagulation activators and separator gel. The aliquots were then centrifuged at 2,500 rpm for 5 min (Eppendorf^® Minispin^® model SPIN 1.000, Hamburg, Germany) to separate the serum. These biological samples were then tested by automated analysis using a commercial Cobas Integra kit (Roche, Boulogne-Billancourt, France) to evaluate the following parameters: creatinine, AST: aspartate aminotransferase, ALT: alanine aminotransferase, uric acid, sodium potassium, chloride, calcium, phosphate, total bilirubin, and phosphatase alkaline.

All patients were followed up with a physical examination and a blood test. The differential white blood cell (WBC) count was analyzed using an XE-5000 hematology analyzer (Sysmex, Kobe, Japan), as per the manufacturer’s protocol. In patients undergoing one-stage surgery, the NLR was calculated from a blood sample measured before IPAA by dividing the absolute neutrophil count by the absolute lymphocyte count. Patients were followed up from the time of IPAA to the onset of pouchitis, loss to follow-up, or until the end of March 2020. The NLR was calculated from a blood sample measured before stoma closure. Patients were followed up from the time of stoma closure to the onset of pouchitis, loss to follow-up, or until the end of March 2020.